A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

NCT00645190 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Galantamine HBr

Sponsor

Xian-Janssen Pharmaceutical Ltd.